An additional promising strategy for DMD is the delivery of DNA vectors that cause the transcriptional machinery in muscle cells to miss out the mutated exons in dystrophin responsible for DMD (exon skipping); this method generates a smaller but functional protein that will prevent the disease occurring. Using antisense oligonucleotides into U7snRNA/AAV vectors, we have shown that this ‘exon skipping’ approach can successfully restore expression of the dystrophin gene in cellular and animal models of DMD. The advantage of AAV based U7snRNA vectors are that they show more sustained expression than naked antisense oligonucleotides. This work is being carried out in collaboration with Aurelie Goyenvalle and Luis Garcia in Versailles, France.